Shotton Hannah R, Broadbent Steven, Lincoln Jill
Department of Anatomy and Developmental Biology, Autonomic Neuroscience Institute, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK.
Auton Neurosci. 2004 Mar 31;111(1):57-65. doi: 10.1016/j.autneu.2004.02.004.
Treatment with alpha-lipoic acid (LA) or evening primrose oil (EPO), individually, fails to prevent diabetes-induced changes in enteric nerves. Since synergy between these treatments has been reported, the aim was to investigate the effectiveness of combined LA/EPO treatment. LA and EPO were administered in the diet (approximately 80 and 200 mg/kg/day, respectively) to control and diabetic (induced by streptozotocin, 65 mg/kg, i.p.) rats. For prevention, treatment started after 1 week and lasted 7 weeks. For reversal, treatment lasted 4 weeks and was initiated after 8 weeks. Nerves supplying the ileum containing vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and noradrenaline (NA) were examined immunohistochemically or biochemically. Diabetes caused a significant increase in VIP-containing cell bodies (p<0.001), decrease in NA content (p<0.01) and loss of CGRP-immunoreactivity. LA/EPO treatment totally prevented diabetes-induced changes in VIP (p<0.001) and CGRP and partially reversed (p<0.05) these changes once they had been allowed to develop. In contrast, treatment had no effect on diabetes-induced changes in NA-containing nerves. Therefore, LA and EPO are only effective at treating diabetes-induced changes in some enteric nerves when administered in combination. However, diabetes-induced changes in NA-containing nerves are resistant to treatment.
单独使用α-硫辛酸(LA)或月见草油(EPO)治疗,无法预防糖尿病引起的肠神经变化。由于已有报道称这些治疗之间存在协同作用,因此本研究旨在探究联合使用LA/EPO治疗的效果。将LA和EPO添加到饮食中(分别约为80和200毫克/千克/天),给予对照大鼠和糖尿病大鼠(通过腹腔注射链脲佐菌素诱导,剂量为65毫克/千克)。为进行预防,在1周后开始治疗,持续7周。为进行逆转治疗,治疗持续4周,并在8周后开始。对供应含有血管活性肠肽(VIP)、降钙素基因相关肽(CGRP)和去甲肾上腺素(NA)的回肠的神经进行免疫组织化学或生化检查。糖尿病导致含VIP的细胞体显著增加(p<0.001),NA含量降低(p<0.01)以及CGRP免疫反应性丧失。LA/EPO治疗完全预防了糖尿病引起的VIP(p<0.001)和CGRP变化,并且在这些变化已经发生后部分逆转了这些变化(p<0.05)。相比之下,该治疗对糖尿病引起的含NA神经的变化没有影响。因此,LA和EPO联合给药时,仅对治疗糖尿病引起的某些肠神经变化有效。然而,糖尿病引起的含NA神经的变化对治疗具有抗性。